借锛涓ㄩ楂绉绘涔芥不锛

扮借锛镐俊澶у戒锛寰澶浜虹╁氨浜借锛姣濡缇界痉虹风凤绉瀛灞澶汉锛界跺涓北澶お瀹搴榫绛绛椋涓剁ュч╁ч存涔风姊锛濂充富瑙ㄧ杩涓娈靛婚涔焦ｇ借缁涓娌昏韩浜°

界跺ㄦ勾剧存浜烘版涓锛借骞朵ｅ绉锛浣涓烘ユх借蹇跺搴互楂存锛澶у杩借插涓璧风借锛涓汉娴烽浼绔椹虹涓や釜搴锛涓烘や姝诲锛浜惧伴楠ㄩ绉绘恒

ｄ缁╁诲涓瀹跺骞寸绌讹垫峰涓㈡灏灏介繁ユ哄颁负澶у璁蹭璁蹭涔借浠ュ扮绌惰灞娌荤规

借绫汇跺璇

借淇瑙ｉ灏辨娑蹭腑界澶ч规界绉绫讳富瑕涓虹缁娣宸寸借锛规界茬搴澧蹇㈠涓烘ユф㈡х借

借涓昏跺ぇ芥变姝ｅ父界寮璧风锛姣濡锛杩浜澧界濡褰卞浜姝ｅ父界扮戒虹х讹浠ヤ典借绗涓朵朵楂с濡褰卞浜姝ｅ父绾㈢灏变虹璐锛褰卞浜姝ｅ父琛灏跨灏变虹圭跺鸿

借璇跺骞朵撅琛娑叉瀵逛杈稿浜哄氨浠ュ浜韪奖锛楠ㄩ绌垮哄浠ョ涓涓杈纭绛妗界瀛灞锛哄娴搴娓涓哄荤妫娴涓╁涓烘规界哄绐绫诲浠ユ村纭板绫诲锛浠存瀵规у拌琛娌荤姝ゅ韬竟挎堕寸韬涓鸿癸涓瀹瑕浠浠涓涓琛甯歌锛璇翠瀹灏辫藉ㄦ╂寮甯搞

借娌荤

ｄ寰浜借板瀹瑕楠ㄩ绉绘

ㄤ涓绾や涓颁袱绉灏挎ユх借浠ュ拌瀵煎缂瑙ｏ澶чㄥ借浜哄ㄤ缂瑙ｇ朵灏辫杩琛楠ㄩ绉绘ユ不借浣杩跺娌荤╁缁娌荤规虹锛瑰浜杩绉跺碉涓涓借ｈ姝よ涓轰绉娌荤借跺┿

1.浼椹垮凹锛煎

2001骞寸涓涓跨ら跺娌荤╀椹垮凹璇锛 BCR-ABL 虫э㈡х缁借90%宸锛ｈ藉琚ぇ澶х瑙ｏ5骞寸瀛浠30%澧颁60%村瑕椹垮凹浣垮浜鸿藉甯镐汉涓风娲伙澶уぇ瑰浜虹娲昏川

2.甯椴椤块皑告

2014骞达缇FDA瑰浣跨ㄥ椴椤块皑告讹ibrutinib锛ㄦユ不㈡ф宸寸借锛 涓村璇楠涓ｈ讳搴涓71锛锛澶辫触不ｈ浣跨ibrutinib跨ゆ杩灞瀛娲荤26涓杈惧75%

3.纾烽告舵跺

2014骞7锛ㄤ瑰娌荤3绉娣宸寸х借纾烽歌3婵PI3K未婵剁瑰跺锛Idelalisib锛峰ㄧ芥涓甯

4.JAK2跺

2014骞12锛缇FDA棣娆℃瑰浣跨JAK2跺锛Ruxolitinib锛娌荤х孩缁澧澶

跺娌荤绫讳技锛 CAR-T 娌荤娉涔琚ㄦユ不ユф宸寸х借棣涓CAR-T涓村璇楠剧ず浜ソ涓村

杩浜板昏蹇灞锛浣跨借浜哄ㄩ楂绉绘瀛不涔澶锛浜村扮┿姝わㄧ寰颁剁典锛瀵归楂绉绘姹涔寰涓ｄ杩㈡х缁借娣宸存х借ㄦ板╃朵涓锛冲浠ユ朵楠ㄩ绉绘浠ワ瀵逛借涓灏辨跺纭╂不

1.Leukemia - Chronic Myeloid - CML: Statistics | Cancer.Net

2. The Bruton's tyrosine kinase 锛BTK锛 inhibitor PCI-32765 锛P锛 in treatment-naive 锛TN锛 chronic lymphocytic leukemia 锛CLL锛 patients 锛pts锛锛 Interim results of a phase Ib/II study J Clin Oncol 2012 锛suppl; abstr 6507锛3. Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia 2014 New England Journal of Medicine: 99710074. Ruxolitinib. Nature Reviews Drug Discovery 11 锛2锛锛 1034

锛浣锛娆灏浜荤澶у诲锛椹ㄨ濉澶у琛娑茶跨ょ╁澹璺ㄥ借界绌堕㈣跨ょ澹ㄥぇ璐瑰板哄跨ゅ╃锛